PHYSICIANS ARE GREATLY CHALLENGED TO PROVIDE
OPTIMAL THERAPY FOR MYCOBACTERIAL ILLNESS IN MULTIPLE DRUG-RESISTANT CASES. RESISTANCE TO DRUGS RESULTS FROM SPONTANEOUS MUTATIONS
IN GENOMA OF THE BACILLI.
AMONG MILLIONS OF NEW CASES OF TB / TL 90% CASES
ARE REPORTED FROM DEVELOPING COUNTRIES, AND 98% OF THEM [TB] LEAD TO DEATH. A VARIETY OF CONDITIONS FAVOR THE DEVELOPMENT
OF DRUG-RESISTANT TB / TL. THE MOST POTENT RISK FACTOR IS CONSIDERED TO BE SUPPRESSED CELLULAR IMMUNITY. WITH EFFECTIVE, TIMELY,
AND PROPER CHEMOTHERAPY THESE PATIENTS HAVE A VERY HIGH CHANCE OF BEING CURED. HOWEVER, COMMONLY IMPROPER USE OF DRUGS, WHILE
REDUCING MORTALITY, RESULTS IN LARGE NUMBERS OF CHRONIC INFECTIOUS CASES, OFTEN WITH MULTIPLE DRUG-RESISTANT BACILLI. MULTIPLE
DRUG-RESISTANT CASES ARE MORE DIFFICULT TO MANAGE. THE OPTIMAL DURATION OF TREATMENT IN THIS SITUATION IS NOT KNOWN.
MULTIPLE DRUG-RESISTANT TB [TUBERCULOSIS] IS CLINICALLY
FOUND EITHER IN PULMONARY AND OR EXTRA PULMONARY FORMS, WHEREAS, THE TL [TUBERCULOID LEPROSY] IS CONFINED ONLY TO SKIN AND
PERIPHERAL NERVES. THE SKIN LESIONS OF TL CONSISTS OF ONE OR A FEW HYPOPIGMENTED MACULES OR PLAQUES. THE PATIENTS OF TL MAY
HAVE ASYMMETRIC ENLARGEMENT OF ONE OR A FEW PERIPHERAL NERVES E.G. ULNAR, POSTERIOR AURICULAR, PERONEAL AND POSTERIOR TIBIAL
NERVES, WITH ASSOCIATED HYPOESTHESIA AND MYOPATHY. FORMATION OF GRANULOMAS IS COMMON FEATURE IN TB / TL LEADING TO CASEOUS
NECROSIS. SUCH TISSUE DISTRUCTIONS BY T-CELLS ARE PATHOGNOMONIC FOR TB / TL MYCOBACTERIAL INFECTIONS / DISEASES.
AUTOPATHY TREATMENT FOR EITHER NATURE OF ILLNESSES IS
SAME AND HIGHLY EFFECTIVE. RECOVERY OF IMMUNITY AND FROM THEIR [TB / TL] SYMPTOM-COMPLEX IS VERY FAST. PATIENTS WITH MINIMAL
ANATOMO-FUNCTIONAL DISTRUCTIONS OF THE ORGANS / TISSUES INVOLVED ARE PREFERRED FOR THE AUTOPATHY TREATMENT. BASED ON THE ALLOPATHY
PARAMEDICAL FINDINGS AND AUTOPATHY INVESTIGATIONS PATIENTS ARE PRESCRIBED ‘TREATMENT-ASSISTS’ IF SO NEEDED. AUTOPATHY
TREATMENT INVOLVES AAA-II THERAPY, ANTIOXIDANTS / VITAMINS, HARRHE – NIMB [INDIAN TERMINOLOGY] APPLICATION, WEEKLY I
/ M INJECTION OF CALCIUM GLUCONATE, AND PER OS WEEKLY ADMINISTRATION OF RIFAMPIN. EXCEPT AAA-II THERAPY OTHER ABOVE DESCRIBED
AGENTS ARE COMMONLY GIVEN FOR NINE TO TWELVE MONTHS. AAA-II TREATMENT IS PRESCRIBED ONLY FOR TWO TO THREE MONTHS. BY THE END
OF THE YEAR OF ABOVE DESCRIBED AUTOPATHY TREATMENTS TB / TL – PATIENTS ARE FOUND FREE FROM MYCOBACTERIAL DISEASES.
